TO THE EDITOR
The skin fragility disorder, recessive dystrophic epidermolysis bullosa (RDEB) results from mutations in COL7A1, leading to reduced or absent type VII collagen (C7) and defective anchoring fibrils at the dermal-epidermal junction (Fine et al., 2014) . Currently, there is no cure, and most individuals develop lifeshortening squamous cell carcinomas (Fine and Mellerio, 2009) . RDEB also has a major health economic burden; wound dressings for a 10-year-old child can cost $680 per day (Kirkorian et al., 2014) , which equates to 4$250,000 annually.
Reported clinical trials of cell-based therapies for RDEB comprise intradermal allogeneic fibroblasts (Petrof et al., 2013; Venugopal et al., 2013) , bone marrow transplantation (Wagner et al., 2010) , intradermal bone marrowderived mesenchymal stromal cells (BM-MSCs) (Conget et al., 2010) , and intravenous BM-MSCs in RDEB adults (El-Darouti et al., 2013; abstract only) . Ex vivo COL7A1 keratinocyte gene therapy is also being evaluated (Siprashvili et al., 2014) .
MSCs are heterogeneous cells that undergo self-renewal or differentiate into mesenchymal lineages (Caplan, 1991) . MSCs also have non-progenitor functions in immune regulation, cell growth, and tissue repair (Phinney and Prockop, 2007; Chen et al., 2008) . Nevertheless, healing is not associated with large numbers of therapeutic MSCs in injured tissues, suggesting that paracrine benefits may modulate inflammatory and immune responses (Baraniak and McDevitt, 2010 Laboratory assessments did not reveal any adverse impact of the BM-MSCs on renal, liver, or bone marrow function. Anti-C7 antibodies were detected by ELISA at baseline in 9/10 participants, but no sera bound to the dermal-epidermal junction by indirect immunofluorescence microscopy. Following MSCs, there were no changes in ELISA or indirect immunofluorescence microscopy data (Supplementary Table S8 online) .
Collectively, the tolerance data appear encouraging, although it should be noted that a zero event rate for a serious AE in just 10 patients is compatible with an upper 95% confidence interval of over 30%.
With regard to secondary outcome measures, the data are summarized in Supplementary Table S9 online. Skin biopsies revealed no increase in C7 and no new anchoring fibrils at day 60. Fluorescence in situ hybridization analysis did not show donor-cell chimerism.
Birmingham epidermolysis bullosa severity score (BEBSS) and global severity score questionnaires were completed for all the 10 participants (Supplementary Figures S2 and S3 online) . Mean parentreported pain score was lower at 60 days than at baseline (mean difference: − 5.5 points; 95% confidence interval (CI): − 16.3, 5.3); similar changes were seen at day 180 (mean difference − 3.0 (−14.7, 8.7) (Supplementary Figure S4 online). Change in mean disease severity (total BEBSS) was − 5.2 points (95% CI: − 10.7, 0.3), and change in mean BEBSS total body surface area (TBSA%) was -5.9 points from baseline to day 60 (−15.3, 3.5); similar changes were seen at 180 days for both BEBSS measures (Supplementary Figure S5 online) . Mean global severity score was 7.0 at baseline and 4.6 at day 60 (mean difference: − 2.4 (95% CI: − 3.4, − 1.4). Corresponding mean change at day 180 was − 1.6 (−3.0, − 0.24). Mean quality of life score (higher is worse) reported by parents was 41.9 at baseline and 37.5 at day 60 (mean difference: − 4.4; 95% CI: − 8.1, − 0.7) and 39.0 at day 180 (mean difference: − 2.9; 95% CI: − 7.5, 1.8) (Supplementary Figure S6 online ).
Qualitative data (telephone interviews at 9 months) revealed impressions for better wound healing in all the 10 subjects and for less skin redness in 9/10 with clinical benefits lasting for~4-6 months (Figure 1 and Supplementary  Figures S7 and S8 online) . These data are presented in Supplementary Tables S10 and S11 online. Median blister counts at baseline, day 60, and 180 were 5.5, 3.5, and 3.5, respectively (Supplementary Figure S9 online) . Mean suction blister times were limited to just two time points: 10.2 at baseline and 11.9 at day 100 (mean difference: 1.7; 95% CI: − 0.5, 3.9); individual data are shown in Figure 2 .
Overall, the changes in efficacy outcomes were promising, although it should be remembered that this is an unblinded study of participants who are keen to help, thus giving a potential for positive information bias.
Many of the subjective verbatim interviews, however, disclosed perceived benefits, such as better sleep (child and parents), a parent being able to return to work part-time because of reduced caring needs, and a family being able to plan their first vacation together and so on. Thus, although further studies of BM-MSCs in RDEB are needed to demonstrate efficacy, address mechanisms of action, and determine optimal cell dosage, our current findings indicate some benefits for daily life.
Practically, MSCs can be given as a bolus over 10 minutes without sedation, and the child can resume normal activities within 1 hour. If MSCs were given in the clinic at the doses used in this trial, repeated every 6 months, we estimate that the costs would be similar to current biologics licensed to treat patients with chronic inflammatory diseases but with the potential for cost-neutrality or savings based on reduced dressing needs and shortened carer time.
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We studied 24 MDS patients with non-blastic skin infiltrate and compared them with 20 leukemia cutis patients. This study adheres to the declaration of Helsinki principles, and patient consent for experimentals was not required because the French laws consider human tissue left over from surgery as discarded material. Detailed patient data are given in Supplementary Table S1 online.
Between 1995 and 2012, 800 patients were diagnosed with MDS in Hôpital-Saint-Louis, Paris. One hundred and fifty patients underwent skin biopsy, and we identified 24 skin involvements by non-blastic tumor cells, defined as medium-sized immature myeloid cells (Figure 1 ) with (i) abundant eosinophilic cytoplasm and (ii) twisted nuclei or pseudo-Pelger-Huet anomaly, a specific myelodysplasia marker on blood smears (Shetty et al., 2001) . The tumor cells had a combined myeloid and monocytic phenotype, expressing both myeloperoxydase (100% of cases) and CD163 (100%) or CD68 (96%). They did not express CD34, CD117, or CD56. The proliferative index with Mib-1 was low (o10% positive cells) in 56% of cases, or intermediate (10 to 66% positive cells) in 44% of cases, but never high (≥66% positive cells). Mature neutrophils and normal CD3+ lymphocytes were numerous (46% and 100% of cases, respectively) and edema was frequent (67%).
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